Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Norepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.96 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.96 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.96 |
| ▸ | BLM | P54132 | 6/20 | 0.96 |
| ▸ | MAPT | P10636 | 6/20 | 0.96 |
| ▸ | RECQL | P46063 | 4/20 | 0.96 |
| ▸ | APEX1 | P27695 | 4/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.96 |
| ▸ | MEN1 | O00255 | 4/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norepinephrine SCHEMBL29399946 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL2429869 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL2610 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL29371849 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL3489077 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL29460319 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL2609 | 0.98 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL17504429 | 0.96 | TDP1 (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL317206 | 0.96 | BLM (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL4155242 | 0.96 | BLM (0.96) | TDP1KDM4EBLMMAPTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227562-A1 | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor | PFIZER INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7268161-B2 | Comprehensive pharmacologic therapy for treatment of obesity including cysteine | Vidas, Arrett & Steinkraus, P.A. | 2007-09-11 | — | — | US | disclosed |
| EP-1778241-A1 | COMBINATION OF A SELECTIVE NORADRENALINE REUPTAKE INHIBITOR AND A PDEV INHIBITOR | Pfizer Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006016262-A1 | COMBINATION OF A SELECTIVE NORADRENALINE REUPTAKE INHIBITOR AND A PDEV INHIBITOR | PFIZER LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| US-20050065190-A1 | Comprehensive pharmacologic therapy for treatment of obesity including cysteine | Vidas, Arrett & Steinkraus, P.A. | 2005-03-24 | — | — | US | disclosed |
| US-6759437-B2 | WEIGHT LOSS FOR A PATIENT NOT SUFFERING FROM DEPRESSION BY ADMINISTERING A SELECTIVE SEROTONIN REUPTAKE INHIBITOR, (E.G., PHENTERMINE), 5-HYDROXYTRYPTOPHAN, CYSTEINE, VITAMIN B6, AND VITAMIN C; SIDE EFFECT REDUCTIONS | Vidas, Arrett & Steinkraus, P.A. | 2004-07-06 | — | — | US | disclosed |
| US-20020094969-A1 | Comprehensive pharmacologic therapy for treatment of obesity including cysteine | Vidas, Arrett & Steinkraus, P.A. | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065190-A1 | Comprehensive pharmacologic therapy for treatment of obesity including cysteine | TPH1, HTR6, CTH | ADRB2 1678/4885ADRB1 1792/4885ADRA2A 895/4885 |
| US-20020094969-A1 | Comprehensive pharmacologic therapy for treatment of obesity including cysteine | TPH1, HTR6, CTH | ADRB2 1678/4885ADRB1 1792/4885ADRA2A 895/4885 |
| US-20090227562-A1 | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor | PDE4A, PDE12, PDE4B | ADRB2 48/4885ADRB1 31/4885ADRA2A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.